FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast CancerJulia A. Beaver, Patricia Cortazar, Amna Ibrahim et al.|Clinical Cancer Research|2015Cited by 377
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysisJennifer Gao, Tatiana M. Prowell, Joyce Cheng et al.|The Lancet Oncology|2019Cited by 299
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1Preeti Narayan, Julia A. Beaver, Jennifer Gao et al.|Clinical Cancer Research|2020Cited by 185
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated TumorsJaleh Fallah, Julia A. Beaver, Michael H. Brave et al.|Clinical Cancer Research|2022Cited by 180
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Richard Pazdur, Erik Bloomquist et al.|Clinical Cancer Research|2018Cited by 115